NEW YORK, Aug. 8, 2023/PRNewswire/ — Ligandal Inc, an early-stage genetic medicine biotech company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Commercial Officer. Nuwal brings 20 years of experience in the biopharmaceutical industry, including positions with small and large pharmaceutical companies.
“We are delighted to welcome Tushar to Ligandal. His experience negotiating multi-million dollar pharmaceutical transactions and his drive to expand the Ligandal platform will be invaluable to our growth,” said Andre Watson, Chairman and CEO of Ligandal Inc.
Nuwal is a veteran of the global pharmaceutical industry. His leadership spans RD, manufacturing, product and launch management, operations, business and corporate development, licensing, portfolio and business strategy. His most recent position was Vice President of Polypid Inc, where he headed the business development and operations department. Previously, he was CEO of BD
Nuwal’s career is marked by impressive achievements. He has successfully led and closed transactions worth more than $2 billion and launched products that generate more than $1 billion in annual revenue. His experience includes positions with Pfizer Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma and Fresenius Kabi.
Nuwal holds a BS in Chemical Engineering and Economics from Rensselaer Polytechnic Institute, an LL.M. in Transactions and Intellectual Property Law from Northwestern University, a Graduate Diploma in Finance from New York University and is currently pursuing a Certificate of Science program. doctors at Harvard University.
“I am delighted to join Ligandal in advancing our cell and gene therapy platform. I am especially inspired by Andre Watson, our founder and Forbes 30 under 30 recipient in Healthcare. I am excited to collaborate with him and our top team This team includes Dr. Adam Stein, our chief scientific officer and former midsize pharmaceutical industry executive, and Dr. Daniel Fagbuyi, Board Member, Chief Medical Officer, Executive Vice President of Government Affairs, formerly of Biodefense and Obama Administration Public Health, former adviser to HHS, FDA and CDC, and a veteran of the US Army, together we will further the company’s vision and mission,” Nuwal said.
About Ligandal – Ligandal is at the forefront of genetic medicine, focusing on innovative solutions for oncology, rare genetic disorders, and biodefense. Leveraging cutting-edge nanotechnology, Ligandal is committed to developing therapies that have the potential to transform lives and shape the future of medicine.
IR and Media Contact: Robert Sereny
rob@ligandal.com
press@ligandal.com
1 (718) 801-3773
Logo – https://mma.prnewswire.com/media/2170202/Ligandal_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/ligandal-inc-nombra-a-tushar-nuwal-director-de-operaciones-y-director-comercial-301894599.html
